370 results on '"Espié, Marc"'
Search Results
2. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
3. Non-genetic indications for risk reducing mastectomies: Guidelines of the national college of French gynecologists and obstetricians (CNGOF)
4. Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer
5. Ten-Year Outcomes of Hypofractionated Postmastectomy Radiation Therapy of 26 Gy in 6 Fractions
6. Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)
7. Intraoperative Radiotherapy for Breast Cancer in Elderly Women
8. The germline genetics of mild-to-moderate penetrance: An intriguing role of PRAME in multiple carcinogenesis
9. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
10. Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification
11. Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab
12. Cancer lobulaire infiltrant : épidémiologie, histoire naturelle, principes thérapeutiques
13. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
14. 10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment
15. The Multidisciplinary Meeting
16. Hormonal Treatment of Breast Cancer
17. Table S1 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
18. Figure S4 from A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases
19. Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
20. Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies
21. Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women
22. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
23. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
24. Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
25. Cancer Risk in Women Exposed to Diethylstilbestrol in Utero
26. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
27. Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study)
28. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone
29. 18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer
30. 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
31. Abstract 4101: ADRENALINE, an atlas for drug and breast cancer survival interaction: Comedications at diagnosis and impact on breast cancer mortality of the French breast cancer cohort (n=235,375)
32. p53 in breast cancer subtypes and new insights into response to chemotherapy
33. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
34. Generators and the Template Method Pattern. A Paradigm for Combinatorial Experimentation
35. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
36. Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy
37. Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
38. Chapitre 9 - Qualité de vie après cancer
39. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer
40. Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?
41. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
42. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
43. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim
44. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
45. Should FDG PET/CT be used for the initial staging of breast cancer?
46. Coordinateurs
47. Grossesse et cancer du sein : le point de vue de l'oncologue
48. Diagnostic et décision dans le cancer du sein à un stade précoce
49. Cancer du sein : données épidémiologiques Chiffres d’incidence et de mortalité
50. Facteurs de décision des traitements médicaux, conférences de consensus et recommandations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.